Volunteer s Death Unrelated To Covaxin: Bharat Biotech We cannot confirm if the volunteer received the study vaccine or a placebo as the study is blinded, the vaccine major noted. PTI outlookindia.com 2021-01-09T20:56:07+05:30
After the death of a 42-year-old volunteer in Bhopal, who took a dose of Covaxin in the clinical trial of Bharat Biotech s Covaxin, further spurred controversy over the emergency approval of the firm s covid vaccine, Bharat Biotech denied that the vaccine was the cause of the volunteer s death.
Vaccine maker Bharat Biotech on Saturday said the death of a volunteer in Bhopal, who took a shot of its COVID-19 vaccine Covaxin as part of the Phase III clinical trials, was not related to the medication.
Volunteer s death in Bhopal not related to vaccine, may be of poisoning: Bharat Biotech
India
Published: Saturday, January 9, 2021, 20:43 [IST]
New Delhi, Jan 09: Vaccine maker Bharat Biotech on Saturday said the death of a volunteer in Bhopal, who took a shot of its COVID-19 vaccine Covaxin as part of the Phase III clinical trials, was not related to the medication.
Representational Image As per the post-mortem report issued by the Gandhi Medical College, Bhopal that the site received from the Bhopal Police, the probable cause of death was due to cardio respiratory failure as a result of suspected poisoning and the case is under police investigation as well, the Hyderabad-based firm said in a statement.
US nurse tests positive week after receiving COVID-19 vaccine
The 45-year-old US nurse became sick while working in COVID-19 unit. He got the chills and later came down with muscle aches and fatigue. Vaccinated US nurse contracts COVID-19, expert says shot needed more time to work (Image Source: Twitter/@Reuters)
Share
Updated: Dec 30, 2020, 08:17 PM IST
A US nurse has tested positive for COVID-19, eight days after having received a vaccine shot. Matthew W, who works as an ER nurse at two hospitals in San Diego, received the jab on December 18. Speaking to ABC10 News, he said that after receiving the vaccine, his arm was sore for a day but he suffered no other side effects.
Updated Dec 23, 2020 | 12:21 IST
The minister s health is stable and he is responding to treatment, a bulletin issued by the hospital said on Thursday. He was admitted to the hospital on December 15. Haryana Health Minister Anil Vij | Photo Credit: ANI
Chandigarh: Haryana Health Minister Anil Vij on Wednesday said he has been shifted from the ICU to a room of Medanta Hospital in Gurugram after he had tested positive for COVID-19 on December 5. He was admitted to the hospital on December 15 in a critical condition from the Haryana government s Post-Graduate Institute of Medical Sciences (PGIMS) in Rohtak where he had received convalescent plasma therapy.
ROHTAK: The condition of Haryana Health Minister Anil Vij, who is undergoing treatment for COVID-19 at the Medanta Hospital in Gurugram, is stable and his vitals parameters are normal, Dr AK Dubey, Medical Superintendent, of the hospital on Thursday. Haryana Health Minister is undergoing treatment at the intensive care unit (ICU) ward of Medanta hospital in Gurgaon. His health condition is stable and his vitals parameters are normal, Dubey said.
Vij, who had tested positive for coronavirus after taking a trial dose of Bharat Biotech s COVID-19 vaccine Covaxin was recently referred to Medanta Hospital Gurugram.A team of doctors from Medanta had reached Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences (PGIMS) Rohtak for the treatment of the Haryana Minister.